Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 14, Issue 11, 1996, Pages 2959-2967

  Saltz, L B ^a   Kanowitz, J ^a   Kemeny, N E ^a   Schaaf, L ^a   Spriggs, D ^a   Staton, B A ^a   Berkery, R ^a   Steger, C ^a   Eng, M ^a   Dietz, A ^a   Locker, P ^a   Kelsen, D P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN; LOPERAMIDE; ONDANSETRON;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0008461578     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.11.2959     Document Type: Article

References (31)

1. Kunimoto T, Nitta K, Kanaka T, et al: Antitumor activity of 7-ethyl-10[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
2. Hsiang YH, Hertzberg RP, Hecht SM, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
3. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
4. Hsiang YH, Lihou M, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I - DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
5. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638, 1989
6. Eng WK, Faucette L, Johnson RK, Sternglanz R: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755-760, 1988
7. Liu LF: DNA topoisomerases: Enzymes that catalyze the breaking and rejoining of DNA. Crit Rev Biochem 15:1-24, 1983
8. Wang JC: DNA Topoisomersases. Ann Rev Biochem 54: 665-697, 1985
9. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
10. Rothenberg ML, Eckert JR. Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
11. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
12. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16-20, 1992
13. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
14. Takeuchi S, Noda K, Yakushiji M, et al: Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 11:224, 1992 (abstr)
15. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologie and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470, 1970
16. Moertel CG, Schutt AF, Reitemeier RJ, et al: Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101, 1972
17. Muggia FM, Creaven PJ, Hansen HH, et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56:515-521, 1972
18. Cohen AM, Minsky BD, Schilsky RL: Colon cancer, in Devita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 929-967
19. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330:1136-1142, 1994
20. Sasaki Y, Ohtsu A, Shimada Y, et al: Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 86: 1096-1098, 1994 (letter)
21. Miller AB, Hoogstrated B, Staquet M: Reporting of cancer treatment. Cancer 47:207-214, 1981
22. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Marcel Dekker, 1992
23. Kano Y, Suzuki K, Akutsu M, et al: Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 50:604-610, 1992
24. Sams JP, Su P, Slatter JG: In vitro studies on the effect of cotherapy on carboxylesterase-mediated bioactivation of the anticancer agent CPT-11 (U-101440E) to its active metabolite SN-38. Proceedings of the Fourth International ISSX Meeting, Poster #129, Seattle, WA, 1995
25. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin. Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
26. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
27. Leischman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. J Clin Oncol 13:1303-1311, 1995
28. Petrelli N, Douglas HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
29. Parnes H, Tait N, Conley B, et al: A phase I study of CPT-11, weekly bolus 5-FU and leucovorin in patients with metastatic cancer. Oncol Rep 2:1131-1134, 1995
30. Shimada Y, Sasaki Y, Sugano K, et al: Combination phase I study of CPT-11 (CPT-11) combined with continuous infusion 5- fluorouracil (5-FU) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 12:a575, 1993 (abstr)
31. Abigerges D, Armand JP, Chabot GG, et al: High dose intensity of CPT-11 administered as single dose ever 3 weeks: The Institute Goustave Roussy experience. Proc Am Soc Clin Oncol 12:133, 1993 (abstr)